Research news

Research Update May 2025 – prepared by Klaire Exarchou

Clinical Trials

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023

Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study

Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

Current Management Updates

Current Management of Neuroendocrine Tumour Liver Metastases

Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms

Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors

Management of functional neuroendocrine tumors

Basic Science Research

The Molecular Biology of Midgut Neuroendocrine Neoplasms

Clinical Care Papers

Nutritional aspects in neuroendocrine neoplasms. bridging the gap between dietary interventions and cancer care strategies: a scoping review

Research update January 2024 – NET update copy

Clinical Trials – Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study3

Basic Science – Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

Reviews and Clinical Papers

Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences

Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors

Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas

Frequent Presence of Lymphovascular Invasion in Small Rectal Neuroendocrine Tumors on Immunohistochemical Analysis.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumours

Additional malignancies in patients with neuroendocrine tumours: analysis of the SwissNET registry

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastroenteropancreatic Neuroendocrine Tumors and Unknown Primary Sites

Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.

The Ki-67 labelling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors